BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 1-Year High at $7.94

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hit a new 52-week high during trading on Monday . The company traded as high as $7.94 and last traded at $7.94, with a volume of 4483 shares changing hands. The stock had previously closed at $7.85.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BCRX shares. JMP Securities raised their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

BioCryst Pharmaceuticals Stock Down 0.4 %

The stock has a fifty day simple moving average of $6.59 and a 200-day simple moving average of $5.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. During the same period in the prior year, the company posted ($0.28) earnings per share. The firm’s revenue was up 34.9% compared to the same quarter last year. Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Steven K. Galson acquired 21,940 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $5.49 per share, with a total value of $120,450.60. Following the completion of the transaction, the director now owns 51,551 shares of the company’s stock, valued at $283,014.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Steven K. Galson purchased 21,940 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $5.49 per share, for a total transaction of $120,450.60. Following the completion of the purchase, the director now directly owns 51,551 shares of the company’s stock, valued at approximately $283,014.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Helen M. Thackray purchased 30,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was purchased at an average cost of $5.86 per share, with a total value of $175,800.00. Following the acquisition, the insider now owns 272,139 shares in the company, valued at $1,594,734.54. The disclosure for this purchase can be found here. Insiders have purchased 103,601 shares of company stock worth $596,338 in the last ninety days. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Leisure Capital Management acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $173,000. Bank of New York Mellon Corp boosted its position in shares of BioCryst Pharmaceuticals by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after acquiring an additional 86,249 shares in the last quarter. Diversified Trust Co increased its stake in BioCryst Pharmaceuticals by 18.0% in the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 3,774 shares during the period. CWM LLC raised its position in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Finally, Tidal Investments LLC bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $282,000. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.